Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin. RESEARCH DESIGN AND METHODS: Patients were randomized to once-daily open-label treatment with oral semaglutide 14 mg (n = 412) or empagliflozin 25 mg (n = 410) in a 52-week trial. Key end points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands addressed efficacy-related questions: treatment policy (regardless of trial product discontinuation or rescue medication) and trial product (on trial product without rescue medication) in all randomized patients. RESULTS: Four hundred (97.1%) patients in the oral semaglutide group and 387 (94.4%) in the empagliflozin group completed the trial. Oral semaglutide provided superior reductions in HbA1c versus empagliflozin at week 26 (treatment policy –1.3% vs. –0.9% [–14 vs. –9 mmol/mol], estimated treatment difference [ETD] –0.4% [95% CI –0.6, –0.3] [–5 mmol/mol (–6, –3)]; P < 0.0001). The treatment difference in HbA1c significantly favored oral semaglutide at week 26 for the trial product estimand (–1.4% vs. –0.9% [–15 vs. –9 mmol/mol], ETD –0.5% [95% CI –0.7, –0.4] [–6 mmol/mol (–7, –5)]; P < 0.0001) and at week 52 for both estimands (P < 0.0001). Superior weight loss was not confirmed at week 26 (treatment policy), but oral semaglutide was significantly better than empagliflozin at week 52 (trial product −4.7 vs. −3.8 kg; P = 0.0114). Gastrointestinal adverse events were more common with oral semaglutide. CONCLUSIONS: Oral semaglutide was superior to empagliflozin in reducing HbA1c but not body weight at 26 weeks in patients with type 2 diabetes uncontrolled on metformin. At week 52, HbA1c and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide was well tolerated within the established safety profile of GLP-1 receptor agonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in the randomised, open-label, multinational 52-week PIONEER 2 trial, oral semaglutide 14 mg resulted in a significantly greater reduction in CRP compared with empagliflozin 25 mg.23”
In the citing paper
“Study designs for these double-blind, randomized controlled trials have been published previously [18–21].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [20]
In the citing paper
“In PIONEER 2, oral semaglutide reduced CRP by 30%, whereas empagliflozin had no effect despite similar approximately 4% weight loss (24).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [24]
In the citing paper
“In the PIONEER program, four thyroid malignancies occurred in semaglutide-treated patients, versus one in the comparator group”
From Safety of Semaglutide (2021) · cites this paper as [15]
In the citing paper
“The ‘PIONEER’ series of trials [21–30] demonstrated that oral semaglutide has a positive impact on average HbA1c levels and weight reduction compared with several other drug classes (SGLT-2 inhibitor, DPP-4 inhibitor, another GLP-1RA, insulin and placebo).”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [22]
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationStatistical Analysis With Missing Data
Ghosh, S. (1988) · Technometrics · doi:10.1080/00401706.1988.10488446 · Cited by 4,576
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Self-citationSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“†An episode that is severe, according to theADAclassification (requires assistanceof anotherperson to actively administer carbohydrate, glucagon, or other corrective action) (29).”
BackgroundUser’s manual for the SF-12v2 health survey
Ware, J., Kosinski, M., Bowker, D., Gandek, B., Ware, J. E., & Turner‐Bowker, D. M. (2002) · Cited by 1,085
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Self-citationSorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Self-citationPratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594
Self-citationPratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 586
Self-citationTranscellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist
Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7047 · Cited by 553
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Self-citationAhrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30092-x · Cited by 495 · cited 1×
“7%) was similar to previous observations with injectable GLP-1RAs (6–11%) (4,33,34).”
ResultAroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0749 · Cited by 493
Self-citationAroda, V. R., Bain, S. C., Cariou, B., Piletič, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30085-2 · Cited by 464
Roden, M., Weng, J., Eilbracht, J., Delafont, B., Kim, G., Woerle, H. J., & Broedl, U. C. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70084-6 · Cited by 450
Rosenstock, J., Allison, D., Birkenfeld, A. L., Blicher, T. M., Deenadayalan, S., Jacobsen, J. B., Serusclat, P., Violante, R., Watada, H., Davies, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.2942 · Cited by 421
Self-citationSemaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412
Self-citationHäring, H.-U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Broedl, U. C., Woerle, H. J., & on behalf of the EMPA-REG MET Trial Investigators (2014) · Diabetes Care · doi:10.2337/dc13-2105 · Cited by 400
Kovacs, C. S., Seshiah, V., Swallow, R., Jones, R., Rattunde, H., Woerle, H. J., Broedl, U. C., & on behalf of the EMPA‐REG PIO™ trial investigators (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12188 · Cited by 387
Ridderstråle, M., Andersen, K. R., Zeller, C., Kim, G., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70120-2 · Cited by 378
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes
Häring, H.-U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Woerle, H. J., Broedl, U. C., & on behalf of the EMPA-REG METSU Trial Investigators (2013) · Diabetes Care · doi:10.2337/dc12-2673 · Cited by 371
Dahl-Jørgensen, K., Brinchmann-Hansen, O., Hanssen, K. F., Sandvik, L., & Aagenaes, O. (1985) · BMJ · doi:10.1136/bmj.290.6471.811 · Cited by 360
Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30192-5 · Cited by 351
Self-citationSemaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
Vilsbøll, T., Bain, S. C., Leiter, L. A., Lingvay, I., Matthews, D., Simó, R., Helmark, I. C., Wijayasinghe, N., & Larsen, M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13172 · Cited by 318
Self-citationPieber, T. R., Bode, B., Mertens, A., Cho, Y. M., Christiansen, E., Hertz, C. L., Wallenstein, S. O. R., Buse, J. B., Akın, S., Aladağ, N., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30194-9 · Cited by 287
Self-citationNauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014) · Diabetes Care · doi:10.2337/dc13-2761 · Cited by 284
Bretz, F., Posch, M., Glimm, E., Klinglmueller, F., Maurer, W., & Rohmeyer, K. (2011) · Biometrical Journal · doi:10.1002/bimj.201000239 · Cited by 172
Dalton, M., Finlayson, G., Hill, A. J., & Blundell, J. E. (2015) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2015.57 · Cited by 125
International Council for Harmonization
Dhandia, D., Jain, S., Shukla, V. K., Sharma, N., Yadav, P., & Arora, S. (2025) · Routledge eBooks · doi:10.4324/9781003500971-15 · Cited by 75
Aroda, V. R., Saugstrup, T., Buse, J. B., Donsmark, M., Zacho, J., & Davies, M. J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13804 · Cited by 71
Koch, G. G. (2007) · Statistics in Medicine · doi:10.1002/sim.2923 · Cited by 21
Cited by
Ndumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., Coresh, J., Baker-Smith, C. M., Carnethon, M. R., Després, J.-P., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001186 · Cited by 1,405
Advances in oral peptide therapeutics
Drucker, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0053-0 · Cited by 646
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Metadata
- Authors
- Rodbard, H. W., Rosenstock, J., Canani, L. H., Deerochanawong, C., Gumprecht, J., Lindberg, S. Ø., Lingvay, I., Søndergaard, A. L., Treppendahl, M. B., Montanya, E., PIONEER 2 Investigators, Cruz, P., Loredo, L. D., Luquez, C., Moisello, M., Augusto, G. A., Castro, M., Canani, L., Akrap, B., Bulum, T., Rahelic, D., Sunic-Grcic, I., Tusek, S., Avramidis, I., Benroubi, M., Didangelos, T., Karousos, G., Pagkalos, E., Sampanis, C., Somali, M., Domboróczki, Z., Faludi, P., Gaál, Z., Kis-Gombos, P., Kocsis, G., Marton, Z., Sudár, Z., Buscemi, S., Di Carlo, A., Dotta, F., Gambineri, A., Lauro, D., Maranghi, M., Arciszewska, M., Gumprecht, J., Matuszewska, K., Skokowska, E., Stasinska, T., Feofanova, S., Filippova, E., Galstyan, G., Gaysina, L., Kunitsyna, M., Suplotova, L., Antic, S., Djukic, A., Mitrovic, M., Pesic, M., Stokic, E., Jodar, E., Martínez, E., Raya, P. M., Montanya, E., Portillo, C. M., Vera, M. P., Fernández, M. R., San Jose, P., Riera, M. T., Boonyavarakul, A., Deerochanawong, C., Sriwijitkamol, A., Ajani, D., Armas, E., Barbel-Johnson, K., Bartilucci, D., Bonabi, G., Busch, R., Butuk, D., Cannon, K., Chase, C., Chaykin, L., Cheekati, V., Davis, T., Delgado, B., Farris, N., Graves, M., Ha, C., Harper, L., Herring, S., Hewitt, M., Hsia, D., Jackson, R., Jardula, M., Joyce, M., Juarez, M., Kapoor, A., Karounos, D., Kayne, D., Lacour, A., Ledesma, G., Lingvay, I., Lipetz, R., Lomboy, J., Lynd, S., Morawski, E., Morin, R., Murphy, R., Overcash, J. S., Pullman, J., Rodbard, H. W., Rosenstock, J., Ruoff, G., Steenkamp, D., Toro, H., Trachtenbarg, D., Tulloch, B., Weisbrot, A., & Wright, A.
- Affiliations
- Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Novo Nordisk (Denmark) (DK)
- ORCID
- Lindberg, Søren Østergaard
- Augusto, Gustavo Akerman
- Bulum, Tomislav
- Avramidis, Iakovos
- Didangelos, Triantafyllos
- Buscemi, Silvio
- Dotta, Francesco
- Gambineri, Alessandra
- Lauro, Davide
- Maranghi, Marianna
- Galstyan, Gagik
- Boonyavarakul, Apussanee
- Sriwijitkamol, Apiradee
- Busch, Robert
- Herring, Sharon
- Hsia, Daniel
- Overcash, J. Scott
- Steenkamp, Devin
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-10-07
- Volume
- 42
- Issue
- 12
- Pages
- 2272-2281
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2974621372
- Cited by
- 463
- References
- 37
- Citations by year
- 2026: 53 · 2025: 85 · 2024: 78 · 2023: 55 · 2022: 64 · 2021: 59 · 2020: 60 · 2019: 8
- FWCI
- 38.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Use Siena air (University of Siena) (submittedVersion)
- Lume (Universidade Federal do Rio Grande do Sul) (submittedVersion, cc-by-nc-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- oral semaglutide, empagliflozin, type 2 diabetes, metformin failure, GLP-1 receptor agonists, SGLT2 inhibitors, glycemic control, HbA1c, weight loss, gastrointestinal adverse effects, drug safety, treatment policy estimand
- MeSH terms
- Semaglutide, Administration, Oral, Adult, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.